In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 201 to 210 of 382

TitleTypeExpected publication date
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Mental health guidelinesNICE guidelineTBC
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NICE guidelineTBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Technology appraisal guidance
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]Technology appraisal guidanceTBC
Nemolizumab for treating prurigo nodularis [ID6451]Technology appraisal guidanceTBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]Technology appraisal guidanceTBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All